Impact of Prior Chemotherapy or Radiation Therapy on Tumor Mutation Burden in NSCLC
Authors:
Sushma Jonna, Ari M. Vanderwalde, Jorge J. Nieva, Kelsey Anne Poorman, Michelle Saul , Xinyu von Buttlar, John Y Hu, Stephen V. Liu
Background
Higher tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC) correlates with increased expression of tumor-specific neo-antigens and with clinical efficacy of immune check point inhibitors.1
Nivolumab plus ipilimumab improved progression-free survival in patients with NSCLC and high tumor mutation burden.2
Tissue samples subject to TMB analysis may be obtained after exposure to cytotoxic chemotherapy or radiation therapy – both of which introduce somatic mutations in DNA and can influence the number of identified mutations.
The role of TMB as a potential predictive marker for immunotherapy is evolving, and the impact of prior therapy on TMB could influence interpretation.
Methods
Eligible cases were from patients with confirmed NSCLC, available clinical annotation and tumor molecular profiling including TMB analysis at a CLIA-certified genomics laboratory (Caris Life Sciences, Phoenix, AZ) using the Illumina NextSeq platform.
NGS was performed on genomic DNA isolated from FFPE tumor samples using the NextSeq (592-genes).
Tumor mutational burden (TMB) was estimated from 592 genes (1.4 megabases [MB] sequenced per tumor) by counting all nonsynonymous missense mutations found per tumor that had not been previously described as germline alterations.
Treatment history was obtained for each patient under an IRB approved protocol to determine whether patients had received chemotherapy or radiation therapy in the year prior to collection of the tissue subject to TMB analysis.
Data analysis was performed using either the Wilcoxon rate test or the chi-square test of deviance to evaluate whether TMB was statistically significantly different between groups, correcting for smoking status or oncogene status (R software).
Conclusions
Though cytotoxic chemotherapy and radiation therapy can introduce somatic mutations, prior exposure to either was not associated with a significant difference in TMB.
TMB was higher when the specimen source was from a metastatic site compared to the primary site.
Prior exposure to therapy did not impact TMB after adjusting for presence of an oncogene.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept,” you consent to the use of all cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.